Dermatology

HomeAbout UsFacultyGerald G. Krueger, M.D.

Gerald G. Krueger, M.D.

Gerald G. Krueger, M.D.

Professor of Dermatology, Benning Presidential Endowed Chair

  • B.A., 1962, Union College
  • M.D., 1966, Loma Linda University
  • Residency in Dermatology, 1969-1972, University of Colorado
  • Board Certification in Dermatology

Clinical and Research Interests

  • Dr. Krueger is a world-renowned expert in the area of psoriasis, having been involved with both laboratory investigation as well as multiple clinical studies. He is the recipient of the Taub International Award for Psoriasis Research and a National Psoriasis Foundation Lifetime Achievement Award. His other clinical interests include disorders of hair and hair loss. His current research interests are: a) clinical trials with new agents that target specific inflammatory pathways that lead to psoriasis, b) discovery of genes and gene-sets that lead to the variable forms of psoriasis, such as psoriatic arthritis and, c) the genes and/or gene-sets that increase comorbidities that associate with psoriasis, such as obesity and type 2 diabetes.

Selected Publications

  • Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng BJ, Soltani-Arabshahi R, Rakkhit T, Goldgar DE, Krueger GG. Association between IL13 Polymorphisms and Psoriatic Arthritis is modified by smoking. J Invest Dermatol, 2009.
  • Rakkhit T, Panko JM, Christensen TE, Wong B, Nelson T, Papenfuss J, Hansen CB, Callis Duffin K, Krueger GG. Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response. Br J Dermatol, 160(5), 1083-9, 2009.
  • Callis Duffin K, Wong B, Horn EJ, Krueger GG. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol, 60(4), 604-8, 2009.
  • Li Y, Liao W, Chang M, Schrodi SJ, Bui N, Catanese JJ, Poon A, Matsunami N, Callis Duffin KP, Leppert MF, Bowcock AM, Kwok PY, Krueger GG, Begovich AB. Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol, 129(3), 629-34, 2009.
  • Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet, 41(2), 199-204, 2009.
  • Li Y, Chang M, Schrodi SJ, Callis Duffin KP, Matsunami N, Civello D, Bui N, Catanese JJ, Leppert MF, Krueger GG, Begovich AB. The 5q31 variants associated with psoriiasis and Crohn's disease are distinct. Hum Mol Genet, 17(19), 2978-85, 2008.
  • Garcia VE, Chang M, Brandon R, Li Y, Matsunami N, Callis Duffin KP, Civello D, Rowland CM, Bui N, Catanese JJ, Krueger GG, Leppert MF, Begovich AB, Schrodi SJ. Detailed genetic characterization of the interleukin-23 receptor in psoriasis. Genes Immun, 9(6), 546-55.
  • Chang M, Li Y, Yan C, Callis Duffin KP, Matsunami N, Garcia VE, Cargill M, Civello D, Bui N, Catanese JJ, Leppert MF, Krueger GG, Begovich AB, Schrodi SJ. Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun, 9(2), 176-81, 2008.
  • Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K. Efficiacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 371(9625), 1675-84, 2008.
  • Cargill M, Schrodi, SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Honigberg LA, Civello D, Catanese JJ, Leong Du, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB, A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis risk genes, Am J Hum Gen 80:273-90, 2007.
  • Krueger GG, Langley RG, Leonardi C, Yeilding N, Cynthia G, Yuhua W, Dooley LT, Lebwohl M, for the CNTO1275 Psoriasis Study Group, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis, NEJM 356:30-42, 2007.
  • Benson NR, Papenfuss J, Wong R, Motaal A, Tran V, Panko J, Krueger GG, An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting, J Invest Dermatol Oct 2006, 126(10):2234-41.
  • Christensen TE,, Callis KP, Papenfuss J, Hoffman MS, Hansen CB, Wong B, Panko J, Krueger GG, Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin plaque and thick plaque psoriasis, and their associated phenotypes, J Invest Dermatol 126:2397-2403, Nov 2006.
  • Herron MD, Hinkley M, Hoffman MS, Papenfuss J, Hanson CB, Callis KP, Krueger GG, Impact of obesity and smoking on psoriasis presentation and management, Arch Dermatol 141:1527-1534, 2005.
  • Carlin CS, Feldman SR, Krueger JG, Menter A, and Krueger GG, A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis, J Am Acad Dermatol 50:859-866, 2004.
  • Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory-effector T lymphocytes. A randomized phase II trial of recombinant human LFA-3/IgG1 fusion protein (Alefacept). N Engl J Med 2001;345:248-255
  • Krueger GG, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation (NPF) patient membership survey. Arch Dermatol 2001;137:280-284
  • Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM. A position paper - two considerations for psoriasis patients and their professional care providers: What defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:280-285
  • Krueger GG, Jorgensen CM, Petersen MJ, Mansbridge JN, Morgan JR. Use of cloned genetically modified human fibroblasts to assess long-term survival in vivo. Human Gene Ther 1997;8:523-532
  • Lieb LM, Liimatta AP, Bryan RN, Brown BD, Krueger GG. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp in vitro. J Pharm Sci 1997;86:1022-102
  • Krueger GG, Pitcher C Liimatta AP, Knapp TL, Miller KJ II, Wilkins DG, Rollins DE. Uptake of agents of the environment into human hair: use of amino acids as simulants of exposure vs. codeine. J Cutan Med Surg 1996;1:66-73
  • Petersen M, Kaplan J, Morgan J, Jorgensen C, Li L-T, Schmidt L, Li H-L, Kwan M, Krueger G. Blood levels of human transferrin in athymic mice after transplantation of a dermal matrix containing genetically modified 3T3 cells. J Invest Dermatol 1995;104:171-176
  • Gilhar A, Krueger GG. Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice. Arch Dermatol 1987;123:44-50
  • Wojciechowski Z, Pershing LK, Huether S, Leonard L, Burton SA, Higuchi WI, Krueger GG. An experimental skin sandwich flap on an independent vascular supply for the study of percutaneous absorption. J Invest Dermatol 1987;88:439-446
  • Eyre RW, Krueger GG. Interrelations of the skin's response to injury and disease activity in psoriasis. Br J Dermatol 1982;106:153-159
  • Krueger GG, Chambers DA, Shelby J. Involved and uninvolved skin from psoriatic subjects: Are they equally diseased? Assessment by analysis of skin transplanted to congenitally athymic (nude) mice. J Clin Invest 1981;68:1548-1557